An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated
Sponsor: Bristol-Myers Squibb
Listed as NCT03329846, this PHASE3 trial focuses on Melanoma and Skin Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 21 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 16 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE3
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .